This system is under development and not for clinical use.
OneTra
Standard Care
Cited next step
Sources stay in view
A workspace for case details, evidence, and follow-up — not a live analysis.
How it works
Explore OneTra
Sample walkthrough. This uses a labelled fictional oncology note and a previously captured response. It is not a live analysis and does not prove accuracy for other cases.
New case · sample file
SYNTH-ONC-2026-09-15_nsclc_alk.txt · TXT, DOCX, or text-bearing PDF up to 10 MB
A synthetic adult NSCLC note is attached. Nothing is sent to a model when you view this walkthrough.
Extracted details · review before Analyse
Cancer type
NSCLC
Stage
IV
Biomarkers
ALK_FUSION
ECOG
0
Line of therapy
1L
Histology
adenocarcinoma
Prior therapy
Blank — not in the note
Age
Blank — not in the note
Captured Standard Care sample · not generated now
First-line targeted therapy with an ALK inhibitor (alectinib, lorlatinib, crizotinib, ceritinib, or brigatinib) for patients with ALK translocations.
Source: PDQ · Non-Small Cell Lung Cancer Treatment (PDQ®), 15 May 2025.
Example source passage
“ALK inhibitors (for patients with ALK translocations).”
Standard Care is grounded in PDQ sources with citations. Related research is labelled separately. A drug checker verifies applicable claims; it does not replace PDQ synthesis, and silence is not treated as verification.
Standard CarePDQ-grounded next step with source links
Related researchConfirmed-context research, labelled as related when it is not a direct citation
Follow-upLongitudinal review when more than one dated report is available
Saved casesAnswers and citations can be reopened in your workspace
Oncology Now
Recent research
Last reviewed 15 September 2026. These summaries are curated from original sources and are not live news. They are not OneTra analysis results.
Regulatory approval (accelerated)
FDA grants accelerated approval to camizestrant for ESR1-mutated advanced breast cancer
On 4 September 2026 the FDA granted accelerated approval to camizestrant (Etcamah) with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is found during aromatase-inhibitor plus CDK4/6 inhibitor therapy. In SERENA-6, median progression-free survival was 16.0 versus 9.2 months. Overall survival data were not mature. Continued approval may depend on confirmatory trials.
FDA approves daraxonrasib for previously treated metastatic pancreatic cancer
On 26 August 2026 the FDA approved daraxonrasib (Rasonque), a RAS-family inhibitor, for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or who cannot receive multiagent chemotherapy. In the randomized RASolute 302 trial of 500 patients, median overall survival was 13.2 versus 6.7 months compared with standard chemotherapy. Median progression-free survival was 7.2 versus 3.6 months.
FDA expands Trodelvy for first-line triple-negative breast cancer
On 24 June 2026 the FDA approved sacituzumab govitecan-hziy (Trodelvy) in two first-line settings for unresectable locally advanced or metastatic triple-negative breast cancer: as a single agent when PD-1/PD-L1 therapy is not an option, and with pembrolizumab when tumors express PD-L1 (CPS ≥ 10). In ASCENT-03, median progression-free survival was 9.7 versus 6.9 months versus chemotherapy. Overall survival data were still immature.
It is a workspace that brings case details, standard-care evidence, related research, and follow-up information together so an oncologist can review a case in one place.
How do I start?
Sign in with Google, choose New case, upload a report, review the extracted details, then Analyse.
Where do its answers draw evidence from?
Standard Care draws on PDQ sources with citations. Related research is labelled separately. A drug checker verifies applicable claims and does not replace PDQ synthesis.
Can I review the extracted details?
Yes. Extracted fields are shown for review and editing. Missing facts stay blank.
Can I reopen a saved case?
Yes. Saved cases stay in your workspace with their answer and citations. Other accounts cannot see them.